In the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial, the highest risk of cardiovascular death was seen in patients with the highest EPO dose, suggesting that EPO resistance through inflammation and/or functional iron deficiency might be a possible link [6]. Here, EPO is linked to Iron deficiency anemia.